Tuesday, September 16th, 2014
5:45p.m., Fuqua School of Business, Lilly Classroom
Light reception to follow
RSVP at https://duke.qualtrics.com/SE/?SID=SV_eLmdqBrevDcRp3v
An estimated 15% of drugs sold in the world are fake—in Africa and Asia this figure can range from 10% to 30%, compromising 10% of the global medicine market. In addition to therapeutic failure and drug resistance resulting from counterfeit medications, anywhere from 30 to 2,500 patients have died from individually recorded instances of counterfeit drug sales every year. Further counterfeit drugs decrease incentives for pharmaceutical companies to enter markets, potentially limiting access to needed drugs.
Sproxil is a U.S.-based company that provides world-class brand protection in emerging markets through software and services that work anywhere there are mobile phones. Sproxil allows consumers to verify product genuineness within seconds through SMS texts. This technology allows patients to ensure at the moment of purchase that their drugs are from reputable providers; limiting the chance of negative health impact of counterfeit drugs and products. To date, Sproxil has verified over 6 million products, giving everyone along the supply chain the power to quickly and confidently verify the authenticity of a drug at each step, ensuring patient safety. For more information about Sproxil, visit http://sproxil.com/
Speaker Alden Zecha serves as CFO and Strategist of Sproxil, where he is responsible for the overall strategy, finance and administration of the company, Zecha brings to the role more than 25 years of broad-range executive expertise in operations, strategy and finance, and vast experience from work in more than 20 countries. Prior to joining Sproxil, Zecha co-founded and served as CFO of ultra-luxury travel company PrivatSea and as CFO of Rethos, a sustainability and corporate social responsibility social media website. Zecha received his MSE and BSE with honors in chemical engineering from Princeton University, where he was a United Technologies Scholar, and holds a certificate in finance from the University of Virginia’s Darden School of Business.
5:45p.m., Fuqua School of Business, Lilly Classroom
Light reception to follow
RSVP at https://duke.qualtrics.com/SE/?SID=SV_eLmdqBrevDcRp3v
An estimated 15% of drugs sold in the world are fake—in Africa and Asia this figure can range from 10% to 30%, compromising 10% of the global medicine market. In addition to therapeutic failure and drug resistance resulting from counterfeit medications, anywhere from 30 to 2,500 patients have died from individually recorded instances of counterfeit drug sales every year. Further counterfeit drugs decrease incentives for pharmaceutical companies to enter markets, potentially limiting access to needed drugs.
Sproxil is a U.S.-based company that provides world-class brand protection in emerging markets through software and services that work anywhere there are mobile phones. Sproxil allows consumers to verify product genuineness within seconds through SMS texts. This technology allows patients to ensure at the moment of purchase that their drugs are from reputable providers; limiting the chance of negative health impact of counterfeit drugs and products. To date, Sproxil has verified over 6 million products, giving everyone along the supply chain the power to quickly and confidently verify the authenticity of a drug at each step, ensuring patient safety. For more information about Sproxil, visit http://sproxil.com/
Speaker Alden Zecha serves as CFO and Strategist of Sproxil, where he is responsible for the overall strategy, finance and administration of the company, Zecha brings to the role more than 25 years of broad-range executive expertise in operations, strategy and finance, and vast experience from work in more than 20 countries. Prior to joining Sproxil, Zecha co-founded and served as CFO of ultra-luxury travel company PrivatSea and as CFO of Rethos, a sustainability and corporate social responsibility social media website. Zecha received his MSE and BSE with honors in chemical engineering from Princeton University, where he was a United Technologies Scholar, and holds a certificate in finance from the University of Virginia’s Darden School of Business.
RSS Feed
